The GLP-1 drugs are the latest class to show a benefit in patients, this time with OSA, but like other tools have nontrivial side effects, cost concerns, and patient persistence issues that balance out the headline benefits. The size of the underlying patient populations, which are expected to surpass 1.3 billion globally by 2050, as well as the under penetration of CPAP treatment, which Andrew ballparks at 15% or less in many markets, reinforces the analysts argument
Continue reading Tirzepatide vs semaglutide: How do they compare
Lilly grew revenue 44.7% in 2025, is launching its biggest new product today, and trades 17.7% below its 52-week high
Today, well break down the science behind peptides for hair loss
By Manuel Bowman Fact-checked by Payton Olsen Last updated June 2026